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Background: The RTS,S/AS01E malaria vaccine is being assessed in 
Malawi, Ghana and Kenya as part of a large-scale pilot 
implementation programme. Even if impactful, its incorporation into 
immunisation programmes will depend on demonstrating cost-
effectiveness. We analysed the cost-effectiveness and public health 
impact of the RTS,S/AS01E malaria vaccine use in Malawi. 
Methods: We calculated the Incremental Cost Effectiveness Ratio 
(ICER) per disability-adjusted life year (DALY) averted by vaccination 
and compared it to Malawi’s mean per capita Gross Domestic Product. 
We used a previously validated Markov model, which simulated 
malaria progression in a 2017 Malawian birth cohort for 15 years. We 
used a 46% vaccine efficacy, 75% vaccine coverage, USD5 estimated 
cost per vaccine dose, published local treatment costs for clinical 
malaria and Malawi specific malaria indicators for interventions such 
as bed net and antimalarial use. We took a healthcare provider, 
household and societal perspective. Costs were discounted at 3% per 
year, no discounting was applied to DALYs. For public health impact, 
we calculated the DALYs, and malaria events averted. 
Results: The ICER/DALY averted was USD115 and USD109 for the 
health system perspective and societal perspective respectively, lower 
than GDP per capita of USD398.6 for Malawi. Sensitivity analyses 
exploring the impact of variation in vaccine costs, vaccine coverage 
rate and coverage of four doses showed vaccine implementation 
would be cost-effective across a wide range of different outcomes. 
RTS,S/AS01 was predicted to avert a median of 93,940 (range 
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20,490–126,540) clinical cases and 394 (127–708) deaths for the three-
dose schedule, or 116,480 (31,450–160,410) clinical cases and 484 
(189–859) deaths for the four-dose schedule, per 100 000 fully 
vaccinated children. 
Conclusions: We predict the introduction of the RTS,S/AS01 vaccine in 
the Malawian expanded programme of immunisation (EPI) likely to be 
highly cost effective.
Keywords 
Malaria, Malawi, cost-effectiveness, RTS, S, vaccine, Markov Chain, 
Modelling
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Introduction
Malaria is one of the most important causes of under-five 
morbidity and mortality in Malawi. Over the past 10 years, 
Malawi has substantially scaled up available malaria control 
tools, such as insecticide treated bed nets (ITN) and artemisinin- 
based combination (ACTs) treatments. During this period, the 
national parasite prevalence in young children has reduced 
by 44% (from 43% to 24% in 2010 and 2017 respectively) and 
mortality due to malaria has halved1–3. In 2017, the National 
Malaria Control Programme laid out a five-year Malaria stra-
tegic plan (2018–2022). The strategy has two main aims; to 
reduce malaria incidence by at least 50% from a 2016 baseline 
of 386 per 1000 population to 193 per 1000 and reduce 
malaria deaths by at least 50% from 23 per 100,000 popu-
lation to 12 per 100,000 population by 2022. As of 2019, 
there were over 286, 000 malaria cases per 1,000 people and 
13 malaria attributable deaths per 100,000 people4. With the 
current trajectory, there is still need of additional malaria control 
measures to meet these goals and to eventually eliminate malaria. 
There is a need to further enhance the interventions already 
in place but it is also critical that we explore additional tools in 
the battle against malaria. One of this is the introduction of 
prophylactic vaccination against P. falciparum parasite.
The RTS,S/AS01
E
(henceforth RTS,S) is the first malaria 
vaccine to receive a conditional approval for use in under-five 
children living in moderate-to-high malaria burden settings 
following a large-scale Phase III study in Sub-Saharan Africa. 
RTS,S vaccine. The vaccine’s clinical efficacy against all 
clinical episodes of malaria was 51% (95% CI, 47- 55) in the 
5–17 month age group after 12 months following the first 
3 doses across trial all sites. The efficacy decreased to 46% (95% 
CI, 41.7–49.5) after 18 months follow up for the same group 
and dosage. The vaccine efficacy for the trial period of 
48 months median follow up (after the first dose) was 26% (95% 
CI, 21–31) among subjects who received a 3-dose schedule 
and 39% (95% CI, 34–43) among those who received a 
4 dose schedule5.
Malawi is one of three countries participating in a large-scale 
pilot implementation programme of the RTS,S AS01
E
 (GSK) 
malaria vaccine (henceforth RTS,S)6. Even if impactful, its 
cost-effectiveness will be a crucial determinant of subsequent 
introduction7. Malawi is supported by Gavi, the global vaccine 
alliance, for funding existing vaccines and for introduction 
of any new vaccines. Gavi eligibility is based upon a World 
Bank determined inflation-adjusted Gross National Income 
per capita (GNI pc) below a US$1,580 threshold8, Malawi’s 
current GNI pc is $3809. Malawi is required to finance a 
proportion of vaccine cost, equivalent to US$0.20 per dose.
RTS,S has been predicted to be highly cost-effective in areas in 
sub-Saharan Africa with moderate-to-high malaria transmission 
across different model approaches10. However, health care 
programmes, vaccination schedules and related cost assumptions 
vary considerably between LMIC countries. Cognisant of this, 
national policy makers increasingly seek in-country evidence to 
inform their decisions. There are no published RTS,S national 
level cost-effectiveness data for Malawi or for regional countries. 
An intervention is considered cost-effective if the incremen-
tal cost effectiveness ratio (ICER) per disability adjusted 
life years (DALYs) averted is less than three times the GDP 
per capita and is highly cost effective if the ICER per DALY 
averted is less than the per capita GDP11.
We sought to predict the RTS,S cost-effectiveness and public 
health impact in Malawi.
Methods
An intervention is considered cost-effective if the ICER per 
disability-adjusted life year (DALY) averted is less than three 
times the GDP per capita and is highly cost effective if the ICER 
per DALY averted is less than the per capita GDP12.
Model description
We used a Markov static cohort model developed by GSK for 
the RTS,S vaccine that has been validated for sub-Saharan 
Africa; the model is described in depth by Sauboin et al.13. The 
model simulates a birth cohort followed over 15 years under 
fixed-exposure levels of malaria transmission, taking into 
account parameters reflecting healthcare provider and societal 
perspective to calculate the incremental cost effectiveness ratio 
per DALY averted (ICER) of the RTS,S vaccine13.
Figure 1 is a diagrammatic representation of the model. The 
model has compartments susceptible (S), infected (I), clinical 
disease (C) and severe disease (F) divided into six successive 
immunity levels following each infection levels.
The model assumes initial protection against malaria from 
maternal antibodies (M)14. Neonates are considered either 
protected from (M) or are susceptible to (S1) malaria infection. 
Initial immunity is presumed to wane exponentially over three 
months, leaving the child susceptible to infection. An infected 
(I1) child will have asymptomatic parasitaemia which clears 
and susceptibility returns (Si), or the child will develop clinical 
disease (C1). From clinical disease a child may recover (r1) 
or develop severe disease (F1) where they could either survive 
returning to a susceptible state or they could die. Immunity is 
enhanced every level from an asymptomatic state to clinical 
malaria and to severe disease. The model permits up to six 
          Amendments from Version 1
This manuscript has been updated to address comments from 
Reviewers 1 and 2. The main changes are:
The introduction has been expanded as requested by both 
reviewers, which now includes the malaria epidemiology in 
Malawi, vaccine efficacy data and the RTS,S vaccine introduction 
process in Malawi.
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repeated infections to cumulatively increase immunity. Beyond 
six infections, a fixed proportion of children is assumed to 
develop a state of resistance (R).
Model assumptions and inputs
The model uses an estimated 2017 annual birth cohort for 
Malawi and followed for 15 years15. This birth cohort was 
the mean of four prior birth cohorts using the United Nations 
population data15. The model accounts for heterogeneity of 
individual level exposure and a fixed probability of infection 
within each transmission category. The model assumes the 
vaccine efficacy wanes over time. Malaria transmission intensity 
in the model was defined categorically as low, medium or high 
based on Plasmodium falciparum parasite prevalence (PfPR) 
in children aged 2–10 years old of <5%, 5–40% and >40% was 
respectively, using the Malaria Atlas Project16.
Table 1 shows the input parameters used in the model. The 
inputs were point estimates extracted from published litera-
ture or reasonable assumptions. The vaccine price was based on 
previously published assumptions since the product has not yet 
been priced by GSK. The cost of RTS,S vaccine delivery per 
dose was assumed equal to DTP3 (given as part of pentavalent) in 
Malawi17. Service delivery make up the bulk (63%) of vaccine 
delivery costs whilst supply chain and logistics constitute the 
remainder of vaccine delivery costs18. Vaccine delivery costs 
mainly comprise of cold chain management, transportation of 
vaccines to health facilities, waste disposal and additional 
training for health workers. We sought to calculate cost savings 
from a healthcare and household perspective. Societal costs 
are a combination of healthcare and household costs.
The Phase III RTS,S/AS01 trial vaccine schedule of 6, 7, 8 and 
26 months of age and 18-month follow-up results, following 
the third dose, were fitted in the model. Vaccine efficacy against 
clinical and severe malaria in children was 46% (95% 
CI 42–50%) and 34% (95% CI 15–48%) respectively5. Third 
and fourth dose RTS,S coverage were assumed to be 75% and 
60% of the DTP3 dose 1 coverage respectively. The fourth dose 
was assumed to boost the waning efficacy. Access to artem-
isinin combination therapy (ACT) or private dispensaries was 
extracted from the 2014 Malawi Malaria Indicator Survey19.
We used published treatment costs for mild-moderate and 
severe gastroenteritis, respectively20,21, since published treatment 
costs for malaria were outdated or unavailable. These health 
costs including drugs, laboratory investigations, staff salaries and 
facility costs. Where these specific costs were unavailable for 
clinical and severe malaria, we used malaria sequelae costing 
data from Tanzania22, as cost data from Malawi were not 
available. Direct and indirect household costs incurred in care 
seeking were also based on those locally empirically observed 
in gastroenteritis21. Direct household costs included travel, 
consultation fees, treatment sought before and after health facility 
visit and the costs of food and shelter for the carer. Indirect 
costs comprised income lost while caring for the child21. Bed net 
use and access to and usage of ACTs and the proportion of those 
who seek treatment at a private dispensary were derived from 
Figure 1. Model structure. The model assumes two processes for acquisition of immunity, one process that protects against clinical 
malaria of any severity and a faster process that protects against severe malaria. M = maternal protection; S = susceptible; I = infected 
(parasites emerging from the liver); C = clinical disease episode; F = severe disease episode. There are six levels of immunity with 
compartments S, I, C and F divided into six levels. R = resistant; wm = waning of maternal immunity; q = probability of infection; 
s = susceptibility to infection as a function of age; a = probability of asymptomatic infection; r = recovery rate from clinical disease; 
w = waning rate of acquired immunity; r imm = probability of developing full immunity.
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the Malawi Malaria Indicator Survey19. Vaccine price per dose 
has not yet been set by GSK, so we assessed a range of costs 
of USD1, USD5 and USD10. RTS,S delivery in the Malawi 
EPI was taken from the administration cost pentavalent vaccine2. 
The cost of delivery includes all the necessary materials and 
health worker time required to administer a vaccine in the EPI. 
The mean Malawi GDP per capita from 2010 to 2015, as 
reported by the World Bank, was used to compare with the ICER 
per DALY averted28.
Sensitivity analysis
Univariate analysis was conducted by running the model through 
different values of vaccine price and vaccine coverage, as 
shown in Table 3 and Table 4, whilst the other input parameters 
were held constant.
Results
Based on a 15-year cohort of 711,743 children, the model 
calculated an ICER of USD 115 and 109 per DALY averted 
in the health system and the societal perspective respectively 
compared to no vaccination. Based on a vaccine schedule of 
four doses, this is less than the Malawi mean GDP per capita of 
USD 398.6, suggesting that the introduction of RTS,S vaccine 
to the Malawian EPI programme would be highly cost-effective. 
The model predicted 721,768 (95% CI: 529,296–894,991) averted 
clinical malaria cases per year, 14% of current burden. The 
model demonstrated that 117,260 clinical cases and 700 malaria 
attributable deaths would be prevented per 100,000 fully 
vaccinated children per year. The vaccine introduction was also 
very cost effective at an assumed vaccine price of USD 1 and USD 
10 with four doses of the RTS,S vaccine. We predicted cost 
savings for the society, healthcare system and household as 
USD 3,025,521, USD 2,433,777 and USD 591,744, respectively. 
Healthcare costs contributed to over two-thirds of societal costs.
Modelling findings
Table 2 shows the cumulative cost-effectiveness results for 





More than half of the population (54.5%) fell in the moderate intensity category, 42.2% in the high intensity 
category and only 3.4% were in the low intensity category. Assumed fixed seasonal23
Access to case 
management
38%24
Bed net coverage 82% own at least one bed net24
Vaccine efficacy Clinical malaria 46% (95% CI 42% to 50%) 
Severe malaria 34% (95% CI 15% to 48%)
Vaccine schedule In Malawi, the first dose of the RTS,S/AS01 vaccine is expected to be administered to children at 5 months with 
the second and third at one month intervals; the fourth dose is to be given 15–18 months after the third dose. 
Vaccine coverage The coverage of dose 3 of RTS,S was estimated at 75% of DTP3 coverage to account for the challenge in 
reaching older children and also for the difference in schedule of the RTS,S with traditional vaccines such as the 
pentavalent vaccine. Dose 4 coverage of RTS,S was 80% of dose 3.
Cost of vaccination Vaccine delivery costs USD 2.5025 were estimated from the cost of delivering a single dose of the injectable DTP 
vaccine.
Clinical malaria estimated costs USD
Healthcare system USD 8.0220,21. These include drugs, laboratory investigations, staff salaries and facility costs such as laundry, 
kitchen, sanitation and security.
Household- direct USD 1.2120,21. These include transportation costs, costs of consultations, drugs and diagnostics.
Household- indirect USD 0.5026. These are lost income by the carer attributable to the episode of disease
Severe malaria costs USD
Healthcare system USD 12.827 These include drugs, laboratory investigations, staff salaries and facility costs such as laundry, 
kitchen, sanitation and security.
Household- direct USD 14.121 These include transportation costs, costs of consultations, drugs and diagnostics.
Household- indirect USD 4.1321 These are lost income by the carer attributable to the episode of disease
Sequelae costs USD
Healthcare system USD 40.122 The neurological sequelae was adapted by the cost of treatment of malaria sequelae for the 
Tanzanian health system
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vaccine prices of USD 1, USD 5, and USD 10. At USD 5, the 
ICER was 115 USD per DALY averted. At USD 1 vaccine price 
the ICER was USD 40 per DALY averted and at USD 10 the 
ICER was USD 209 per DALY averted. We showed that the 
vaccine would remain very cost-effective even at an inflated 
vaccine price of USD 10 per dose. However, the societal cost 
savings remain unchanged with a change in vaccine price.
Table 3 shows the cumulative public health impact results over 
15 years with comparison of different vaccine coverage versus 
Table 3. Public health impact results cumulative over a period of 15 years.
Absolute vaccine coverage
Events averted 93%β 85% 75% 65% 55%
DALYs 120,101 109,706 96,799 83,893 70,986
malaria cases 13,424,866 12,270,057 10,826,521 9,382,985 7,939,449
severe malaria cases 313,359 286,403 252,709 219,014 185,320
malaria hospitalisations 260,329 237,935 209,943 181,950 153,958
malaria deaths 81,824 74,786 65,987 57,189 48,391
β=coverage of DTP3 in Malawi.







malaria cases 10,826,521 (14%) 721,768 117,260
severe malaria cases 252,709 (11%) 16,847 2,737
malaria hospitalisations 209,943 (11%) 13,996 2,274
malaria deaths 65,987 (11%) 4,993 714.7
Table 2. Discounted cost-effectiveness results over a 15-year period.
Variable No vaccination 6–9m schedule plus 4th dose Cost savings*
USD 1 per dose USD 5 per dose USD 10 per dose
Healthcare system ICER (USD per DALY 
averted)
--- 40 115 209 ---
Societal ICER (USD per DALY averted) --- 34 109 202 ---
DALYs 1,237,356 1,176,557 1,176,557 1,176,557 96,799
Vaccination costs --- 6,334,532 13,573,997 22,623,329 ---
Healthcare system costs 26,396,028 23,962,251 23,962,251 23,962,251 2,433,777
Incremental costs for healthcare system 3,900,755 11,140,220 20,189,552
Household costs 6,576,176 5,984,432 5,984,432 5,984,432 591,744
Societal costs* 32,972,204 29,946,683 29,946,683 29,946,683 3,025,521
Incremental costs for the society 3,309,011 10,548,476 19,597,808
DALY = disability-adjusted life year; ICER = Incremental Cost Effectiveness Ratio. Note 1. Societal costs = health care system + household level costs.
* Cost savings are the difference in costs between no vaccination scenario and vaccination scenario
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the number of malaria clinical cases averted. The number of 
DALYs and malaria cases and deaths avoided are largely dependent 
on the vaccine coverage in the population. At an assumed 
coverage of 75% of DTP3 coverage, the model predicted 
10,826,521 clinical cases averted (Table 4). This is equal to 
721,768 malaria clinical cases per year. The highest number 
of malaria clinical cases avoided was with a 93% vaccine 
coverage which is similar to current DTP3 coverage for Malawi. 
Table 5 shows the comparison in vaccine cost-effectiveness 
between a three-dose schedule and a four-dose schedule with an 
assumed vaccine price of USD 5 per dose. It shows that more 
DALYs are averted with a four-dose schedule than a three-dose 
schedule, but a four-dose schedule has higher societal costs 
because of ancillary costs associated with an additional visit.
Discussion
This analysis has shown that the introduction of the RTS,S 
vaccine in the Malawi EPI would be a highly cost-effective malaria 
intervention. Cost-effectiveness of interventions affects decisions 
to introduce and invest in their sustainable use. Additional 
economic analyses will further inform budget impact, domes-
tic funding required and long-term financial sustainability of 
such interventions. With the Markov model, we predicted the 
incremental cost-effectiveness ratio and public health impact of 
vaccinating children with four doses of RTS,S as recommended 
by WHO in the pilot implementation programme.
As the vaccine price is currently unknown, we tested the model 
at different vaccine prices with other input parameters held 
constant to determine if the vaccine programme would remain 
cost-effective. Our results showed that even at an inflated 
vaccine price of USD 10 per dose, the ICER per DALY 
calculated was USD 209 suggesting the RTS,S vaccination 
programme would remain highly cost-effective. We analysed 
the cost-effectiveness ratio of a three-dose versus a four-dose 
schedule of the RTS,S vaccine programme. Despite higher 
vaccine and delivery costs of the four-dose than three-dose 
schedule, cost-effectiveness is maintained due to greater 
DALYs averted with the four-dose schedule.
Malawi introduced the Rotavirus vaccine (Rotarix, GSK), in 
2012. Similar to RTS,S, Rotarix is a moderately (64%) efficacious 
vaccine against rotavirus acute gastro-enteritis in Malawi29. 
A cost-effectiveness analysis in Malawi found it to be highly 
cost-effective with USD 5.07 ICER per DALY averted with 
GAVI co-financing and USD 74.73 at vaccine market price20. 
Rotarix is expectedly more cost-effective than RTS,S as it is 
delivered in the same schedule and existing vaccine deliver 
infrastructure as other existing EPI vaccines. The first RTS,S 
dose will be at 5 months and the last dose at 24 months. This 
means RTS,S will require a separate immunisation schedule 
driving the vaccine delivery costs higher. In addition, Rotarix is 
an oral vaccine with only two doses priced below USD 2.3 per 
dose whilst RTS,S is an injectable vaccine and has a four-dose 
schedule with a price assumed to be USD 5 per dose.
The WHO harmonisation exercise on RTS,S cost-effective 
analysis for sub-Saharan Africa involved four modelling 
groups: The Institute for Disease Modeling (EMOD-DTK), GSK 
Vaccines (GSK), Imperial College London (Imperial), and the 
Swiss Tropical and Public Health Institute (OpenMalaria)30. 
The EMOD DTK model is a discrete, stochastic, individual-
based model for malaria in either local or spatially distributed 
settings. The model accounts for the combined effect of an 
extensive set of both vector- and human-directed interventions31,32. 
The Imperial College model is a stochastic, individual-based 
simulation of a single population of humans linked to a 
stochastic compartmental model for mosquitoes33. The model 
includes larval stages as well as adult female mosquitoes to 
capture the feedback of vector control that kills adult mosquitoes 
in the population dynamics34. Swiss TPH – OpenMalaria is a 
stochastic, individual-based, single location simulation model 
of malaria in humans35 linked to a deterministic models of 
malaria in mosquitoes36. The simulation model includes sub-
models of infection of humans37, blood-stage parasite densities38, 
infectiousness to mosquitoes as a lagged function of asexual 
parasite density39, incidence of morbidity including severe and 
hospitalisation and mortality40.
The GSK Markov Model has the advantage of considering the 
three categories of transmission (PfPR2<5%, 5≤PfPR≤40%, 
PfPR2-10>40%) and capacity to factor in heterogeneity in 
exposure among individuals for each transmission level. This 








malaria cases 8,504,970 10,826,521
severe malaria cases 200,322 252,709
malaria hospitalisations 166,421 209,943
malaria deaths 52,308 65,987
DALY = disability-adjusted life year.
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from a cohort model nor can it account for possible herd 
protection. The GSK cohort-based model was the optimal option as 
the other models use individual level data which are unavailable 
in Malawi. Our findings were within the confidence bounds of 
116,480 (31,450–160,410) clinical malaria cases averted per 
100,000 vaccinated children as predicted by the other three 
models. The GSK model is unable to capture the effect of herd 
immunity as compared to the three other models which do. 
Should herd immunity occur, cost-effectiveness would be greater 
than our predictions. The modest efficacy of RTS,S and its short 
duration of protection may limit its potential for reducing the 
parasite circulation capacity. Our method provides point esti-
mates but not 95% confidence bounds, the latter which require 
microsimulation on individual data which were unavailable to 
us. The fourth dose of RTS,S was assumed to restore waning 
immunity but recent data has shown the efficacy to be lower 
after dose four.
Models are input dependent. Cost data in Africa are sparse, 
may be out of date or insufficiently robust. Regional data or 
neighbouring country data may be used when available. A malaria 
cost of illness study in Tanzania, Kenya and Ghana estimated 
clinical malaria and severe malaria costs for household and the 
healthcare system41. Where Malawian data were unavailable, we 
used Tanzanian data rather than data from Ghana or Kenya. This 
is because the Tanzanian and Malawian health financing systems 
are similar, both provide government funded free health care 
through primary and referral level systems, and both lack a 
national insurance system or any substantial private health 
sector42. Additionally, direct household cost for clinical malaria 
was more similar for Malawi (USD 0.5) and Tanzania (USD 0.4) 
than it was for Kenya (USD 0.7) and Ghana (USD 4.4) Malawi 
and Tanzania are geographically contiguous and share similar 
malaria epidemiology.
In the absence of published malaria treatment cost data from 
the societal perspective, we used rotavirus empirical cost data. 
Our data on bed net usage, an important model parameter, was 
taken from the 2014 Malaria Indicator Survey19 which preceded 
the national wide bed net campaign that that distributed over 
2.3 million bed nets from November 2014 to February 201524. 
The RTS,S vaccine is a complementary malaria intervention 
whose impact on the reduction malaria morbidity is also 
dependent on the coverage of other interventions such as bed net 
usage.
Population coverage is crucial to the success of any vaccine 
programme43. RTS,S will be given to older children, aged 
5 months, not as part of the standard EPI schedule. Additional, 
the fourth dose of the RTS,S will be administered to children when 
they are about 2 years of age. This booster dose will be outside 
the normal immunisation schedule whilst the first 3 doses will 
be before the measles vaccine which is given at 9 months. In our 
study we assumed the RTS,S dose 3 coverage at 75% of DTP3 
and the fourth dose to be even lower at 80% of RTS,S of the 
third dose44,45. The coverage rate for the measles vaccine has been 
above 80% since 201044,45 even though the vaccine is given to 
older children. Almost all Malawians have been affected by 
malaria, which may translate to high vaccine acceptance despite 
the non-standard schedule.
Conclusion
Introduction of the RTS,S/AS01 vaccine would be a highly 
cost-effective malaria intervention in Malawi. This holds 
regardless of potential changes to key variables for the vaccine 
programme. Following full recommendation  of vaccine use 
by WHO, individual level cost-effective analyses will provide 
more accurate data that can assist other sub-Saharan African 
countries.
Data availability
All data underlying the results are available as part of the article 
and no additional source data are required.
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RTS,S/AS01 malaria vaccine in Malawian children. They authors found that the ICER/DALY averted 
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